PL3482766T3 - Modyfikowane warianty il-2, które selektywnie aktywują limfocyty t regulatorowe do leczenia chorób autoimmunologicznych - Google Patents
Modyfikowane warianty il-2, które selektywnie aktywują limfocyty t regulatorowe do leczenia chorób autoimmunologicznychInfo
- Publication number
- PL3482766T3 PL3482766T3 PL18215282T PL18215282T PL3482766T3 PL 3482766 T3 PL3482766 T3 PL 3482766T3 PL 18215282 T PL18215282 T PL 18215282T PL 18215282 T PL18215282 T PL 18215282T PL 3482766 T3 PL3482766 T3 PL 3482766T3
- Authority
- PL
- Poland
- Prior art keywords
- variants
- cells
- modified
- treatment
- autoimmune diseases
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- 210000003289 regulatory T cell Anatomy 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462070016P | 2014-08-11 | 2014-08-11 | |
| EP15831523.4A EP3180020B1 (en) | 2014-08-11 | 2015-08-10 | Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| EP18215282.7A EP3482766B1 (en) | 2014-08-11 | 2015-08-10 | Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| PCT/US2015/044462 WO2016025385A1 (en) | 2014-08-11 | 2015-08-10 | Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3482766T3 true PL3482766T3 (pl) | 2020-11-16 |
Family
ID=55304526
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18215282T PL3482766T3 (pl) | 2014-08-11 | 2015-08-10 | Modyfikowane warianty il-2, które selektywnie aktywują limfocyty t regulatorowe do leczenia chorób autoimmunologicznych |
| PL15831523T PL3180020T3 (pl) | 2014-08-11 | 2015-08-10 | Modyfikowane warianty il-2, które selektywnie aktywują limfocyty t regulatorowe do leczenia chorób autoimmunologicznych |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15831523T PL3180020T3 (pl) | 2014-08-11 | 2015-08-10 | Modyfikowane warianty il-2, które selektywnie aktywują limfocyty t regulatorowe do leczenia chorób autoimmunologicznych |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US10035836B1 (enExample) |
| EP (2) | EP3180020B1 (enExample) |
| JP (2) | JP6640834B2 (enExample) |
| KR (1) | KR20170035910A (enExample) |
| CN (2) | CN107106654B (enExample) |
| AU (1) | AU2015301936B2 (enExample) |
| CA (1) | CA2955006C (enExample) |
| EA (1) | EA034925B1 (enExample) |
| ES (2) | ES2807260T3 (enExample) |
| HK (1) | HK1243001A1 (enExample) |
| HU (2) | HUE043038T2 (enExample) |
| IL (1) | IL250059B (enExample) |
| MX (2) | MX373296B (enExample) |
| NZ (1) | NZ728175A (enExample) |
| PL (2) | PL3482766T3 (enExample) |
| SG (1) | SG11201700629TA (enExample) |
| SI (2) | SI3482766T1 (enExample) |
| WO (1) | WO2016025385A1 (enExample) |
| ZA (1) | ZA201700381B (enExample) |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3482766T3 (pl) | 2014-08-11 | 2020-11-16 | Delinia, Inc. | Modyfikowane warianty il-2, które selektywnie aktywują limfocyty t regulatorowe do leczenia chorób autoimmunologicznych |
| EA201792250A1 (ru) | 2015-04-10 | 2018-05-31 | Эмджен Инк. | Мутеины интерлейкина-2 для роста регуляторных т-клеток |
| EP3347056A4 (en) | 2015-09-11 | 2019-02-27 | The Board of Trustees of the Leland Stanford Junior University | BIOLOGICALLY RELEVANT ORTHOGONAL CYTOKINE / RECEPTOR COUPLES |
| IL316210A (en) | 2015-10-01 | 2024-12-01 | Heat Biologics Inc | Compounds and methods for connecting type 1 and 2 extracellular complexes as heterologous chimeric proteins |
| US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| KR102687530B1 (ko) * | 2016-05-04 | 2024-07-25 | 암젠 인크 | T-조절 세포의 증식을 위한 인터류킨-2 뮤테인 |
| BR112018074152A8 (pt) * | 2016-05-25 | 2023-01-31 | Hoffmann La Roche | Métodos para determinar um regime de dosagem, métodos para tratar um indivíduo, método para otimizar o tratamento terapeuticamente, agente terapêutico e sistema de rede para determinar uma dose eficaz ou um regime de dosagem para um indivíduo sendo tratado com um agente terapêutico |
| JP2019532996A (ja) | 2016-11-08 | 2019-11-14 | デリニア，インコーポレーテッド | 自己免疫疾患を処置するためのｉｌ−２変異体 |
| MX2019009255A (es) | 2017-02-06 | 2019-11-05 | Orionis Biosciences Nv | Proteínas quiméricas dirigidas y sus usos. |
| EP3585409A4 (en) | 2017-02-27 | 2020-12-02 | Shattuck Labs, Inc. | CHEMERICAL PROTEINS BASED ON CSF1R |
| JP7128195B2 (ja) | 2017-02-27 | 2022-08-30 | シャタック ラボ，インコーポレイテッド | 細胞外ドメインベースのキメラタンパク質の製造方法及び使用方法 |
| EP3585410B9 (en) | 2017-02-27 | 2023-10-04 | Shattuck Labs, Inc. | Vsig8-based chimeric proteins |
| AU2018234810B2 (en) | 2017-03-15 | 2023-05-11 | Pandion Operations, Inc. | Targeted immunotolerance |
| US10676516B2 (en) | 2017-05-24 | 2020-06-09 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| IL271903B2 (en) | 2017-07-11 | 2025-04-01 | Synthorx Inc | Combination of unnatural nucleotides and methods therefor |
| SG11202000939PA (en) * | 2017-08-03 | 2020-02-27 | Synthorx Inc | Cytokine conjugates for the treatment of proliferative and infectious diseases |
| MX2020003351A (es) | 2017-09-27 | 2020-10-12 | Sigilon Therapeutics Inc | Metodos, composiciones y elementos implantables que comprenden celulas activas. |
| MX2020005041A (es) | 2017-11-21 | 2020-10-12 | Univ Leland Stanford Junior | Agonistas parciales de interleucina-2. |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174092B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| CA3086199A1 (en) * | 2017-12-19 | 2019-06-27 | Xencor, Inc. | Engineered il-2 fc fusion proteins |
| AU2018394189B2 (en) * | 2017-12-27 | 2023-12-21 | Kyowa Kirin Co., Ltd. | IL-2 variant |
| EP3743448A4 (en) | 2018-01-26 | 2021-11-03 | Orionis Biosciences, Inc. | XCR1 BINDING AGENTS AND USES THEREOF |
| US11896643B2 (en) | 2018-02-05 | 2024-02-13 | Orionis Biosciences, Inc. | Fibroblast binding agents and use thereof |
| US11534479B2 (en) | 2018-02-16 | 2022-12-27 | Iltoo Pharma | Use of interleukin 2 for treating Sjögren's syndrome |
| CA3115461A1 (en) * | 2018-03-09 | 2019-09-12 | AskGene Pharma, Inc. | Novel cytokine prodrugs |
| MA52662A (fr) * | 2018-03-28 | 2021-02-17 | Ascendis Pharma Oncology Div A/S | Conjugués d'il-2 |
| WO2019191295A1 (en) | 2018-03-28 | 2019-10-03 | Bristol-Myers Squibb Company | Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use |
| WO2019195056A1 (en) | 2018-04-04 | 2019-10-10 | Sigilon Therapeutics, Inc. | Methods, compositions, and implantable elements comprising stem cells |
| IL277713B2 (en) | 2018-04-04 | 2024-09-01 | Sigilon Therapeutics Inc | Implantable particles and related methods |
| KR20210025522A (ko) | 2018-06-25 | 2021-03-09 | 유니버시티 오브 워싱톤 | 강력하고 선택적인 인터루킨 모방체의 드 노보 디자인 |
| WO2020007937A1 (en) | 2018-07-03 | 2020-01-09 | Iltoo Pharma | Use of interleukin-2 for treating systemic sclerosis |
| CA3106520A1 (en) * | 2018-07-13 | 2020-01-16 | Il-2Rx, Inc. | Compounds, compositions, methods, and uses for treating cancer and immunological disorders |
| WO2020023702A1 (en) | 2018-07-25 | 2020-01-30 | AskGene Pharma, Inc. | Novel il-21 prodrugs and methods of use thereof |
| EP4023667A1 (en) * | 2018-08-06 | 2022-07-06 | Medikine, Inc. | Il-2 receptor binding compounds |
| JP7307500B2 (ja) * | 2018-08-06 | 2023-07-12 | メディカイン、インコーポレイテッド | Ｉｌ－２受容体結合化合物 |
| EP3836954B1 (en) | 2018-08-13 | 2025-05-07 | Iltoo Pharma | Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof |
| US10780121B2 (en) | 2018-08-29 | 2020-09-22 | Shattuck Labs, Inc. | FLT3L-based chimeric proteins |
| JP7441826B2 (ja) * | 2018-09-11 | 2024-03-01 | アンブルックス，インコーポレイテッド | インターロイキン－２ポリペプチド抱合物およびその使用 |
| UY38389A (es) | 2018-09-27 | 2020-04-30 | Sigilon Therapeutics Inc | Dispositivos implantables para terapia celular y métodos relacionados |
| CA3118892A1 (en) | 2018-11-08 | 2020-05-14 | Orionis Biosciences, Inc. | Modulation of dendritic cell lineages |
| EP3883956A1 (en) * | 2018-11-20 | 2021-09-29 | University of Washington | Split interleukin mimetics and their use |
| CN111378026A (zh) * | 2018-12-27 | 2020-07-07 | 天津键凯科技有限公司 | 一种制备结合位点可控的peg化生物分子的方法 |
| EP3923974A4 (en) | 2019-02-06 | 2023-02-08 | Synthorx, Inc. | IL-2 CONJUGATES AND METHODS OF USE THEREOF |
| AU2020223293A1 (en) | 2019-02-15 | 2021-08-19 | Integral Molecular, Inc. | Claudin 6 antibodies and uses thereof |
| JP2022520632A (ja) | 2019-02-15 | 2022-03-31 | インテグラル・モレキュラー・インコーポレイテッド | 共通軽鎖を含む抗体及びその使用 |
| CN119143860A (zh) * | 2019-03-29 | 2024-12-17 | 居里研究所 | 具有经修饰的生物活性的白介素-2变体 |
| WO2020219943A1 (en) * | 2019-04-26 | 2020-10-29 | Prolynx Llc | Slow-release cytokine conjugates |
| WO2020236875A1 (en) | 2019-05-20 | 2020-11-26 | Pandion Therapeutics, Inc. | Madcam targeted immunotolerance |
| KR20220034115A (ko) * | 2019-06-14 | 2022-03-17 | 큐진 인크. | 암 치료용 신규한 인터루킨-2 변이체 |
| AU2020323893A1 (en) | 2019-07-26 | 2022-02-17 | Visterra, Inc. | Interleukin-2 agents and uses thereof |
| TW202124385A (zh) | 2019-09-10 | 2021-07-01 | 美商欣爍克斯公司 | 治療自體免疫疾病之il-2接合物及使用方法 |
| CN114853874B (zh) * | 2019-09-10 | 2024-05-17 | 中国医学科学院北京协和医院 | 靶向调节t细胞的长效白介素-2及其在治疗自身免疫病中的应用 |
| CA3160133A1 (en) * | 2019-11-05 | 2021-05-14 | Medikine, Inc. | Il-2rbyc binding compounds |
| BR112022008750A2 (pt) * | 2019-11-05 | 2022-07-19 | Medikine Inc | Composto de ligação de receptor duplo, composição farmacêutica, método para tratar uma doença em um paciente, método para expandir células imunes, método para reforçar uma vacina, método para modificar a resposta imune e ácido nucleico |
| WO2021102063A1 (en) * | 2019-11-20 | 2021-05-27 | Anwita Biosciences, Inc. | Cytokine fusion proteins, and their pharmaceutical compositions and therapeutic applications |
| IL321567A (en) * | 2019-12-13 | 2025-08-01 | Synthekine Inc | Il-2 orthologs and methods of use |
| CN111018961B (zh) * | 2019-12-17 | 2022-03-18 | 北京志道生物科技有限公司 | 白介素-2衍生物 |
| US11633488B2 (en) | 2020-01-10 | 2023-04-25 | Bright Peak Therapeutics Ag | Modified IL-2 polypeptides and uses thereof |
| EP4090674A4 (en) | 2020-01-14 | 2024-01-24 | Synthekine, Inc. | Biased il2 muteins methods and compositions |
| EP4090383A4 (en) | 2020-01-14 | 2024-01-24 | Synthekine, Inc. | IL2 ORTHOLOGIST AND APPLICATION METHOD |
| CN113121670B (zh) * | 2020-01-15 | 2022-11-22 | 天津键凯科技有限公司 | 二取代peg化白细胞介素2及其制备方法、应用 |
| US20230102464A1 (en) * | 2020-01-15 | 2023-03-30 | Jenkem Technology Co., Ltd. (Tianjin) | Method for preparing pegylated biomolecule with controllable binding sites |
| CA3166816A1 (en) | 2020-02-03 | 2021-08-12 | William J. Dower | Il-7r.alpha..gamma.c binding compounds |
| US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
| AU2021231869A1 (en) * | 2020-03-05 | 2022-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Designed IL-2 variants |
| TWI894224B (zh) | 2020-03-06 | 2025-08-21 | 尼姆大學醫學中心 | 用於肌肉萎縮性脊髓側索硬化症之治療的低劑量人類介白素-2 |
| TW202203973A (zh) | 2020-04-22 | 2022-02-01 | 美商默沙東藥廠 | 對介白素-2受體βγc二聚體具偏性且結合至非肽、水溶性聚合物之人類介白素-2結合物 |
| EP4143329A4 (en) | 2020-04-28 | 2024-10-16 | Anwita Biosciences, Inc. | Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications |
| TW202210502A (zh) | 2020-06-03 | 2022-03-16 | 丹麥商阿森迪斯腫瘤製藥有限公司 | 新穎il-2序列及其用途 |
| WO2022009123A1 (en) * | 2020-07-09 | 2022-01-13 | Eutilex Co., Ltd. | Il-2 variants |
| KR20230097094A (ko) | 2020-10-29 | 2023-06-30 | 브리스톨-마이어스 스큅 컴퍼니 | 질환의 치료를 위한 융합 단백질 |
| CA3197344A1 (en) * | 2020-11-04 | 2022-05-12 | William J. Dower | Il-2r.beta.yc binding compounds and uses thereof |
| EP4255466A1 (en) | 2020-12-04 | 2023-10-11 | Visterra, Inc. | Methods of using interleukin-2 agents |
| EP4314033A4 (en) * | 2021-03-31 | 2025-04-23 | Anwita Biosciences, Inc. | FUSION PROTEINS, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC APPLICATIONS |
| KR20240021155A (ko) * | 2021-04-16 | 2024-02-16 | 오리오니스 바이오사이언시즈 인코포레이티드 | Il-2 기반 작제물 |
| US11999771B2 (en) | 2022-04-07 | 2024-06-04 | Medikine, Inc. | IL-7Rαγc ligand immunoglobulin fusion proteins |
| KR20250113390A (ko) | 2022-09-12 | 2025-07-25 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 자폐 스펙트럼 장애 치료에 사용되는 인터루킨-2 |
| WO2024103860A1 (zh) * | 2022-11-18 | 2024-05-23 | 南京诺艾新生物技术有限公司 | 受体亲和力偏好性的定点偶联聚乙二醇化白介素-2突变体及其用途 |
| KR20250114330A (ko) | 2022-11-30 | 2025-07-29 | 인테그럴 몰큘러 인코포레이티드 | 클라우딘 6을 표적하는 항체 및 이의 이중특이적 형식 |
| WO2024121173A1 (en) | 2022-12-05 | 2024-06-13 | Centre Hospitalier Universitaire De Nimes | Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis in a subgroup of patients |
| KR20250133750A (ko) | 2023-01-09 | 2025-09-08 | 오디세이 테라퓨틱스, 인코포레이티드 | 항-tnfr2 항원-결합 단백질 및 그의 용도 |
| CN119708194A (zh) * | 2023-09-28 | 2025-03-28 | 南京诺艾新生物技术有限公司 | Il-22突变体及其制备方法与应用 |
| WO2025129120A2 (en) | 2023-12-15 | 2025-06-19 | Port Therapeutics, Inc. | Use of thermal bioswitches for treating autoimmune diseases |
| WO2025217240A1 (en) | 2024-04-10 | 2025-10-16 | Odyssey Therapeutics, Inc. | Anti-tnfr2 antigen-binding proteins and uses thereof |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4853332A (en) | 1982-10-19 | 1989-08-01 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins |
| US5206344A (en) * | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US5466447A (en) | 1988-06-29 | 1995-11-14 | Amgen Inc. | Method for treating psoriasis |
| EP0378666A4 (en) * | 1988-07-05 | 1992-01-22 | Amgen Inc. | Interleukin ii analogs |
| US5089261A (en) | 1989-01-23 | 1992-02-18 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
| US4902502A (en) | 1989-01-23 | 1990-02-20 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
| US6541610B1 (en) | 1989-09-05 | 2003-04-01 | Immunex Corporation | Fusion proteins comprising tumor necrosis factor receptor |
| US5650150A (en) | 1990-11-09 | 1997-07-22 | Gillies; Stephen D. | Recombinant antibody cytokine fusion proteins |
| US5281698A (en) | 1991-07-23 | 1994-01-25 | Cetus Oncology Corporation | Preparation of an activated polymer ester for protein conjugation |
| CA2188871C (en) | 1993-09-21 | 2001-01-23 | Robert I. Abels | Method for treating psoriasis |
| PL199659B1 (pl) | 1998-02-25 | 2008-10-31 | Merck Patent Gmbh | Białko fuzyjne przeciwciała hu-KS IL2, cząsteczka DNA kodująca białko fuzyjne przeciwciała hu-KS IL2 i sposób wytwarzania białka fuzyjnego przeciwciała hu-KS IL2 |
| DZ2788A1 (fr) * | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
| US6955807B1 (en) | 1998-05-15 | 2005-10-18 | Bayer Pharmaceuticals Corporation | IL-2 selective agonists and antagonists |
| US6348192B1 (en) | 1999-05-11 | 2002-02-19 | Bayer Corporation | Interleukin-2 mutein expressed from mammalian cells |
| SK782002A3 (en) | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| US6602498B2 (en) | 2000-02-22 | 2003-08-05 | Shearwater Corporation | N-maleimidyl polymer derivatives |
| WO2001080889A1 (en) * | 2000-04-26 | 2001-11-01 | National Jewish Medical And Research Center | Product and process for regulation of t cell responses |
| US6689353B1 (en) | 2000-06-28 | 2004-02-10 | Bayer Pharmaceuticals Corporation | Stabilized interleukin 2 |
| DE60138222D1 (de) * | 2000-09-14 | 2009-05-14 | Beth Israel Hospital | Modulierung von il-2 und il-15 vermittelten t zellantworten |
| RU2003129528A (ru) | 2001-03-07 | 2005-04-10 | Мерк Патент ГмбХ (DE) | Способ экспрессии белков, содержащих в качестве компонента гибридный изотип антитела |
| WO2003006501A2 (en) * | 2001-07-11 | 2003-01-23 | Maxygen Holdings, Ltd. | G-csf conjugates |
| CA2455013A1 (en) | 2001-07-27 | 2003-02-13 | Francesca Storici | Systems for in vivo site-directed mutagenesis using oligonucleotides |
| JP2005507870A (ja) | 2001-08-13 | 2005-03-24 | ユニバーシティ・オブ・サザン・カリフォルニア | 低毒性のインターロイキン−２突然変異体 |
| EP1454138B1 (en) * | 2001-12-04 | 2012-01-18 | Merck Patent GmbH | Immunocytokines with modulated selectivity |
| AU2004251145C1 (en) | 2003-06-12 | 2011-04-14 | Eli Lilly And Company | GLP-1 analog fusion proteins |
| WO2005007121A2 (en) | 2003-07-18 | 2005-01-27 | Massachusetts Institute Of Technology | Mutant interleukin-2(il-2) polypeptides |
| JP4842128B2 (ja) * | 2003-07-21 | 2011-12-21 | トランジェーヌ、ソシエテ、アノニム | 新規多機能性サイトカイン |
| CN1930300A (zh) * | 2004-03-05 | 2007-03-14 | 希龙公司 | 预测患者治疗药物耐受性的体外试验系统 |
| RU2006135112A (ru) | 2004-03-05 | 2008-04-10 | Чирон Корпорейшн (Us) | Тест-система in vitro для прогнозирования устойчивости пациента к терапевтическим средствам |
| MX2007009012A (es) | 2005-01-27 | 2007-09-14 | Novartis Vaccines & Diagnostic | Metodos para tratar carcinoma de celulas renales. |
| ATE367167T1 (de) | 2005-02-07 | 2007-08-15 | Novartis Vaccines & Diagnostic | Aufbereitung von aldesleukin zur pharmazeutischen verwendung |
| FR2918770B1 (fr) | 2007-07-10 | 2009-09-11 | Essilor Int | Afficheur destine a etre integre a une paire de lunettes. |
| US8906356B2 (en) | 2007-11-05 | 2014-12-09 | Massachusetts Institute Of Technology | Mutant interleukin-2 (IL-2) polypeptides |
| KR20090103209A (ko) * | 2008-03-27 | 2009-10-01 | (주)한국비엠아이 | 사람 인터루킨-2 동종체 |
| DE102008023820A1 (de) | 2008-05-08 | 2009-11-12 | Aicuris Gmbh & Co. Kg | Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen |
| WO2010085495A1 (en) | 2009-01-21 | 2010-07-29 | Amgen Inc. | Compositions and methods of treating inflammatory and autoimmune diseases |
| IL323000A (en) | 2010-03-05 | 2025-10-01 | Univ Johns Hopkins | Compositions and methods for antibodies and fusion proteins targeted for immune modulation |
| CU23923B1 (es) | 2010-11-12 | 2013-07-31 | Ct De Inmunología Molecular | Polipéptidos derivados de la il-2 con actividad agonista |
| KR20200070407A (ko) | 2010-11-12 | 2020-06-17 | 넥타르 테라퓨틱스 | Ｉｌ-2 부분 및 중합체의 접합체 |
| CN102462837B (zh) | 2010-11-19 | 2016-08-03 | 生物林格斯Ip有限公司 | 抗炎组合物 |
| WO2012088446A1 (en) | 2010-12-22 | 2012-06-28 | Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
| CN102174111B (zh) | 2011-01-25 | 2013-01-09 | 江苏省弗泰生物科技有限公司 | 人白介素2-Fc融合蛋白及其用途 |
| EP2673294B1 (en) * | 2011-02-10 | 2016-04-27 | Roche Glycart AG | Mutant interleukin-2 polypeptides |
| ES2811624T3 (es) | 2011-03-11 | 2021-03-12 | Hopitaux Paris Assist Publique | Régimen de dosificación de IL-2 para tratar lupus eritematoso sistémico |
| EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| WO2013107413A1 (zh) * | 2012-01-19 | 2013-07-25 | 中国科学院上海巴斯德研究所 | 磷酸化途径相关因子在调控调节性t细胞功能中的应用 |
| WO2013177187A2 (en) | 2012-05-22 | 2013-11-28 | Massachusetts Institute Of Technology | Synergistic tumor treatment with extended-pk il-2 and therapeutic agents |
| US20140044675A1 (en) * | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
| CN103193879A (zh) * | 2013-02-07 | 2013-07-10 | 深圳市亚太兴实业有限公司 | 一种聚乙二醇修饰的重组人白介素2的制备方法 |
| US9546203B2 (en) | 2013-03-14 | 2017-01-17 | Amgen Inc. | Aglycosylated Fc-containing polypeptides with cysteine substitutions |
| DK2970486T3 (en) | 2013-03-15 | 2018-08-06 | Xencor Inc | MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS |
| CN103193887B (zh) | 2013-04-03 | 2015-02-04 | 江苏众红生物工程创药研究院有限公司 | 一种重组猪白细胞介素2-Fc融合蛋白及其编码基因和表达方法 |
| US20150017120A1 (en) | 2013-06-13 | 2015-01-15 | Massachusetts Institute Of Technology | Synergistic tumor treatment with extended-pk il-2 and adoptive cell therapy |
| BR112016018288A2 (pt) | 2014-02-06 | 2017-10-10 | Hoffmann La Roche | proteínas de fusão de interleucina 2 e uso das mesmas |
| CN106659757B (zh) | 2014-04-24 | 2022-01-28 | 利兰斯坦福初级大学董事会 | 白介素2的超级激动剂、部分激动剂和拮抗剂 |
| KR20150133576A (ko) | 2014-05-20 | 2015-11-30 | 삼성전자주식회사 | 화학적 개질된 표적화 단백질 및 그의 이용 |
| IL289475B2 (en) | 2014-07-21 | 2023-10-01 | Delinia Inc | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| PL3482766T3 (pl) | 2014-08-11 | 2020-11-16 | Delinia, Inc. | Modyfikowane warianty il-2, które selektywnie aktywują limfocyty t regulatorowe do leczenia chorób autoimmunologicznych |
| WO2016025645A1 (en) | 2014-08-12 | 2016-02-18 | Massachusetts Institute Of Technology | Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker |
| CA2963602A1 (en) | 2014-10-09 | 2016-04-14 | Dana-Farber Cancer Institute, Inc. | Multiple-variable il-2 dose regimen for treating immune disorders |
-
2015
- 2015-08-10 PL PL18215282T patent/PL3482766T3/pl unknown
- 2015-08-10 PL PL15831523T patent/PL3180020T3/pl unknown
- 2015-08-10 JP JP2017507401A patent/JP6640834B2/ja not_active Expired - Fee Related
- 2015-08-10 AU AU2015301936A patent/AU2015301936B2/en not_active Ceased
- 2015-08-10 EP EP15831523.4A patent/EP3180020B1/en active Active
- 2015-08-10 SG SG11201700629TA patent/SG11201700629TA/en unknown
- 2015-08-10 KR KR1020177001917A patent/KR20170035910A/ko not_active Ceased
- 2015-08-10 HU HUE15831523A patent/HUE043038T2/hu unknown
- 2015-08-10 ES ES18215282T patent/ES2807260T3/es active Active
- 2015-08-10 NZ NZ728175A patent/NZ728175A/en not_active IP Right Cessation
- 2015-08-10 HU HUE18215282A patent/HUE051414T2/hu unknown
- 2015-08-10 CN CN201580053284.3A patent/CN107106654B/zh not_active Expired - Fee Related
- 2015-08-10 CA CA2955006A patent/CA2955006C/en active Active
- 2015-08-10 CN CN202110571465.2A patent/CN113234138A/zh active Pending
- 2015-08-10 MX MX2017000833A patent/MX373296B/es active IP Right Grant
- 2015-08-10 HK HK18102706.1A patent/HK1243001A1/zh unknown
- 2015-08-10 SI SI201531284T patent/SI3482766T1/sl unknown
- 2015-08-10 ES ES15831523T patent/ES2717831T3/es active Active
- 2015-08-10 EP EP18215282.7A patent/EP3482766B1/en active Active
- 2015-08-10 WO PCT/US2015/044462 patent/WO2016025385A1/en not_active Ceased
- 2015-08-10 EA EA201790371A patent/EA034925B1/ru active IP Right Revival
- 2015-08-10 SI SI201530637T patent/SI3180020T1/sl unknown
- 2015-08-10 US US15/327,813 patent/US10035836B1/en active Active
-
2017
- 2017-01-11 IL IL250059A patent/IL250059B/en active IP Right Grant
- 2017-01-17 ZA ZA2017/00381A patent/ZA201700381B/en unknown
- 2017-01-18 MX MX2020004206A patent/MX2020004206A/es unknown
-
2019
- 2019-12-26 JP JP2019235716A patent/JP6941664B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL289475A (en) | Molecules that activate t cells are selectively regulated for the treatment of autoimmune diseases | |
| ZA201700381B (en) | Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases | |
| ZA201804458B (en) | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases | |
| IL266178A (en) | Variants of il-2 for the treatment of autoimmune diseases | |
| SG11201609770TA (en) | Combination therapies for the treatment of cancer | |
| IL259281B (en) | History of bipyrazolyl used in the treatment of autoimmune diseases | |
| PL3132034T3 (pl) | Środek terapeutyczny | |
| SI3122358T1 (sl) | Kombinacije FGFR- in CMET-inhibitorjev za zdravljenje raka | |
| PL3277280T3 (pl) | Izomiosmina do zastosowania w leczeniu chorób autoimmunologicznych | |
| GB201410216D0 (en) | Therapeutic | |
| PL3129483T3 (pl) | Terapia skojarzona do leczenia chorób autoimmunologicznych | |
| PL3122349T3 (pl) | Kompozycje do leczenia samotrawienia | |
| GB201415062D0 (en) | Therapeutic | |
| GB201418893D0 (en) | Monolithic body | |
| GB201410334D0 (en) | Therapeutic | |
| GB201414023D0 (en) | Treatment of autoimmune diseases | |
| GB201514909D0 (en) | Treatment of autoimmune diseases | |
| GB201418508D0 (en) | Therapeutic | |
| GB201413719D0 (en) | Therapeutic | |
| GB201410832D0 (en) | Therapeutic | |
| GB201406674D0 (en) | Therapeutic |